Tardy development of safe medicines for children: a Nordic network offers new platform to reduce this inequity
Acta Paediatr
.
2019 Jun;108(6):992-993.
doi: 10.1111/apa.14775.
Epub 2019 Apr 7.
Authors
Estelle Naumburg
1
2
,
Anders Rane
2
,
Thomas Halvorsen
3
4
,
Heidi Glosli
5
,
Tine Brink Henriksen
6
,
Àsgeir Haraldsson
7
,
Jaana Kallio
8
,
Pirkko Lepola
8
Affiliations
1
Department of Clinical Science, Paediatrics, Umeå University, Umeå, Sweden.
2
Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital (Huddinge site), Stockholm, Sweden.
3
Department of Clinical Science, University of Bergen, Bergen, Norway.
4
Department of Paediatrics, Haukeland University Hospital, Bergen, Norway.
5
Institute for Paediatric Research, Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
6
Perinatal Epidemiology Research Unit, Deptartment of Paediatric and Adolescent Medicine, Aahus University Hospital, Aahus, Denmark.
7
Faculty of Medicine, Children's Hospital, University of Iceland, Landspítali - University Hospital, Reykjavik, Iceland.
8
Department of Children and Adolescents, Helsinki University Hospital, Helsinki, Finland.
PMID:
30844088
DOI:
10.1111/apa.14775
No abstract available
MeSH terms
Child
Drug Development*
Humans
Patient Safety*
Pediatrics
Scandinavian and Nordic Countries
Time Factors